GalNAc
Korro Bio Abandons Lead Genetic Disease Drug Candidate KRRO-110 After Disappointing Trial Data
Korro Bio; KRRO-110; Alpha-1 Antitrypsin Deficiency (AATD); RNA editing; clinical trial failure; layoffs; Novo Nordisk partnership; GalNAc platform; biotech strategy shift
Eli Lilly and insitro Collaborate on AI-Driven Metabolic Disease Therapies
Eli Lilly, insitro, AI, metabolic diseases, siRNA, GalNAc, drug discovery, biotechnology, pharmaceutical partnership